# Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation

> **NCT03172234** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ghada Mohammed AboelFadl** · enrollment: 90 (actual)

## Conditions studied

- Effect of Laryngoscopy and Tracheal Intubation

## Interventions

- **OTHER:** oral amantadine sulfate
- **DRUG:** oral gabapentin
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03172234
- **Lead sponsor:** Ghada Mohammed AboelFadl
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-15
- **Primary completion:** 2018-05-15
- **Final completion:** 2018-05-15
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2018-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03172234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03172234, "Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03172234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*